Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.

Journal Article (Journal Article)

Steroid 5-α-reductase type 2 (SRD5A2) V89L and A49T polymorphisms are thought to play a crucial role in the androgen synthesis and metabolic pathway, but their associations with prostate cancer risk remain controversial. To provide a more precise estimation of the associations between V89L and A49T polymorphisms and prostate cancer risk, we performed a meta-analysis using all published case-control studies of prostate cancer since January 1995. We used odds ratio (OR) and its 95% confidence interval (CI) to assess the strength of the association under various genetic models in both overall and stratified analyses. We also calculated the false-positive report probability, the power of the current study, and the observed P value for significant findings. This analysis included 45 eligible studies of a total of 15,562 cases and 15,385 controls, in which no significant associations were found for the V89L polymorphisms under all genetic models. However, small excess prostate cancer risk was associated with the 49T allele in mixed populations compared with the 49A allele (OR = 1.24, 95% CI = 1.02-1.50), and similar results were observed in Caucasians (OR = 1.24, 95% CI = 1.01-1.53). The sensitivity analysis further strengthened the validity of these findings without publication bias. Although there was no overall association between V89L and prostate cancer risk, A49T might play a role in the etiology of prostate cancer among Caucasians. Additional large and well-designed studies are warranted to validate these findings.

Full Text

Duke Authors

Cited Authors

  • Li, Q; Zhu, Y; He, J; Wang, M; Zhu, M; Shi, T; Qiu, L; Ye, D; Wei, Q

Published Date

  • May 2013

Published In

Volume / Issue

  • 40 / 5

Start / End Page

  • 3597 - 3608

PubMed ID

  • 23277398

Electronic International Standard Serial Number (EISSN)

  • 1573-4978

Digital Object Identifier (DOI)

  • 10.1007/s11033-012-2434-x


  • eng

Conference Location

  • Netherlands